Plain-English translation of NCT06548607 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing two versions of CAR-T cell therapy (RD06-04 and RD06-05) in patients with active autoimmune diseases. CAR-T therapy works by removing certain immune cells from your blood, modifying them in the laboratory to target disease-causing cells, and then putting the modified cells back into your body. The study aims to evaluate whether this medication is safe and effective for treating lupus, systemic sclerosis, vasculitis, inflammatory myopathies, and Sjögren's syndrome.
Standard treatments for autoimmune diseases don't work well enough for all patients and often come with significant side effects. This trial is exploring whether the new treatment—which takes a different approach by reprogramming your own immune cells—can help control these diseases more effectively.
You likely qualify if…
You likely don't qualify if…
You will undergo screening visits to confirm your diagnosis and check that your organs can safely tolerate the treatment. If you qualify, your immune cells will be collected through a procedure similar to donating blood. These cells will then be sent to a laboratory where they are modified and grown over several weeks. Once ready, the cells will be reinfused into your body during a hospital visit. You will have multiple follow-up appointments to monitor your safety, how your body responds to the treatment, and whether your disease improves.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Nanjing Bioheng Biotech Co., Ltd.
Enrollment target
~20 participants
Started
September 2024
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peng Yu
Nanjing Bioheng Biotech Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.